First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
TRAX reported narrower Q2 loss of 95 cents per share. Analysts raised price targets for the stock, citing potential for ANB033 in immune diseases.
TRAX lost less money than people expected, which made analysts more hopeful about the company's future medicine. When experts become more optimistic about a company, it can signal they think the business is moving in a better direction.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.